Effects of Isoflavone Supplementation on the Response to Medroxyprogesterone in Premenopausal Women with Nonatypical Endometrial Hyperplasia: A Randomized, Double-Blind, Placebo-Controlled Trial

Overview

Journal Int J Clin Pract

Publisher Wiley

Specialty General Medicine

Date 2022 Dec 19

PMID 36531558

Authors

Zahra Vahedpour

Homa Boroumand

Shirin Tabatabaee Anaraki

Zohre Tabasi

Hossein Motedayyen

Hossein Akbari

Fariba Raygan

Vahidreza Ostadmohammadi

Affiliations

Soon will be listed here.

Abstract

Objective: The purpose of this study was to evaluate the impact of isoflavone supplementation compared with placebo on endometrial histology and serum estradiol levels in premenopausal women with nonatypical endometrial hyperplasia.

Materials And Methods: The present double-blindplacebo-controlled clinical trial was conducted on 100 women with nonatypical endometrial hyperplasia in the age range of 30 to 45 years. Participants were randomly assigned to receive 50 mg of isoflavone ( = 50) or placebos ( = 50) daily for three months. Both groups received the standard treatment of nonatypical endometrial hyperplasia. Endometrial biopsy and blood samples were taken at the baseline and three months after the intervention. The incidence of drug side effects was assessed as well.

Results: After three months, 88.4% of isoflavone-administered subjects had a significant histological improvement compared to 68.9% subjects in the placebo group (=0.02). There were no significant differences between the two groups in the changes of serum estradiol levels and the incidence of drug side effects.

Conclusion: The findings of the present study demonstrated that the coadministration of 50 mg of isoflavones and medroxyprogesterone acetate increases the treatment efficacy in women with nonatypical endometrial hyperplasia. . This trial was registered on the Iranian website for clinical trial registration (https://www.irct.ir/trial/53553).

References

Mueller S, Kling M, Arifin Firzani P, Mecky A, Duranti E, Shields-Botella J . Activation of estrogen receptor alpha and ERbeta by 4-methylbenzylidene-camphor in human and rat cells: comparison with phyto- and xenoestrogens. Toxicol Lett. 2003; 142(1-2):89-101. DOI: 10.1016/s0378-4274(03)00016-x. View

Bitto A, Granese R, Triolo O, Villari D, Maisano D, Giordano D . Genistein aglycone: a new therapeutic approach to reduce endometrial hyperplasia. Phytomedicine. 2010; 17(11):844-50. DOI: 10.1016/j.phymed.2010.03.024. View

Morito K, Aomori T, Hirose T, Kinjo J, Hasegawa J, Ogawa S . Interaction of phytoestrogens with estrogen receptors alpha and beta (II). Biol Pharm Bull. 2002; 25(1):48-52. DOI: 10.1248/bpb.25.48. View

Unfer V, Casini M, Costabile L, Mignosa M, Gerli S, Di Renzo G . Endometrial effects of long-term treatment with phytoestrogens: a randomized, double-blind, placebo-controlled study. Fertil Steril. 2004; 82(1):145-8, quiz 265. DOI: 10.1016/j.fertnstert.2003.11.041. View

Rowe I, Baber R . The effects of phytoestrogens on postmenopausal health. Climacteric. 2021; 24(1):57-63. DOI: 10.1080/13697137.2020.1863356. View

Li J, Li H, Yan P, Guo L, Li J, Han J . Efficacy and safety of phytoestrogens in the treatment of perimenopausal and postmenopausal depressive disorders: A systematic review and meta-analysis. Int J Clin Pract. 2021; 75(10):e14360. DOI: 10.1111/ijcp.14360. View

Rajadurai V, Chivers P, Ayres C, Mohan G, Stewart C, Leung Y . Predictors of endometrial carcinoma in patients with atypical endometrial hyperplasia at a tertiary gynaecological cancer centre in Western Australia. Aust N Z J Obstet Gynaecol. 2021; 61(2):275-283. DOI: 10.1111/ajo.13300. View

Turner J, Agatonovic-Kustrin S, Glass B . Molecular aspects of phytoestrogen selective binding at estrogen receptors. J Pharm Sci. 2007; 96(8):1879-85. DOI: 10.1002/jps.20987. View

Koshiyama M . The Effects of the Dietary and Nutrient Intake on Gynecologic Cancers. Healthcare (Basel). 2019; 7(3). PMC: 6787610. DOI: 10.3390/healthcare7030088. View

10.

Gomez-Zorita S, Gonzalez-Arceo M, Fernandez-Quintela A, Eseberri I, Trepiana J, Portillo M . Scientific Evidence Supporting the Beneficial Effects of Isoflavones on Human Health. Nutrients. 2020; 12(12). PMC: 7766685. DOI: 10.3390/nu12123853. View

11.

Zhang M, Liu X, Holman C . Effect of dietary intake of isoflavones on the estrogen and progesterone receptor status of breast cancer. Nutr Cancer. 2010; 62(6):765-73. DOI: 10.1080/01635581003605979. View

12.

Steinberg F, Murray M, Lewis R, Cramer M, Amato P, Young R . Clinical outcomes of a 2-y soy isoflavone supplementation in menopausal women. Am J Clin Nutr. 2010; 93(2):356-67. PMC: 3021428. DOI: 10.3945/ajcn.110.008359. View

13.

Quaas A, Kono N, Mack W, Hodis H, Felix J, Paulson R . Effect of isoflavone soy protein supplementation on endometrial thickness, hyperplasia, and endometrial cancer risk in postmenopausal women: a randomized controlled trial. Menopause. 2013; 20(8):840-4. PMC: 3934100. DOI: 10.1097/GME.0b013e3182804353. View

14.

Setchell K . Soy isoflavones--benefits and risks from nature's selective estrogen receptor modulators (SERMs). J Am Coll Nutr. 2001; 20(5 Suppl):354S-362S; discussion 381S-383S. DOI: 10.1080/07315724.2001.10719168. View

15.

Fernandez-Montoli M, Sabadell J, Contreras-Perez N . Fertility-Sparing Treatment for Atypical Endometrial Hyperplasia and Endometrial Cancer: A Cochrane Systematic Review Protocol. Adv Ther. 2021; 38(5):2717-2731. DOI: 10.1007/s12325-021-01693-y. View

16.

Taylor C, Levy R, Elliott J, Burnett B . The effect of genistein aglycone on cancer and cancer risk: a review of in vitro, preclinical, and clinical studies. Nutr Rev. 2009; 67(7):398-415. DOI: 10.1111/j.1753-4887.2009.00213.x. View

17.

Gompel A . Progesterone and endometrial cancer. Best Pract Res Clin Obstet Gynaecol. 2020; 69:95-107. DOI: 10.1016/j.bpobgyn.2020.05.003. View

18.

Chantalat E, Valera M, Vaysse C, Noirrit E, Rusidze M, Weyl A . Estrogen Receptors and Endometriosis. Int J Mol Sci. 2020; 21(8). PMC: 7215544. DOI: 10.3390/ijms21082815. View

19.

Rickard D, Monroe D, Ruesink T, Khosla S, Riggs B, Spelsberg T . Phytoestrogen genistein acts as an estrogen agonist on human osteoblastic cells through estrogen receptors alpha and beta. J Cell Biochem. 2003; 89(3):633-46. DOI: 10.1002/jcb.10539. View

20.

Nees L, Heublein S, Steinmacher S, Juhasz-Boss I, Brucker S, Tempfer C . Endometrial hyperplasia as a risk factor of endometrial cancer. Arch Gynecol Obstet. 2022; 306(2):407-421. PMC: 9349105. DOI: 10.1007/s00404-021-06380-5. View